Drug intelligence / Profile preview

QX010N

Development stage: Preclinical
Lead developer: Qyuns Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

QX010N is a preclinical-stage monoclonal antibody being developed by Qyuns Therapeutics for the treatment of pruritus and associated inflammatory skin conditions, including atopic dermatitis and prurigo nodularis. It acts as an inhibitor of the interleukin-31 receptor (IL-31R), blocking the IL-31-mediated signaling pathway that plays a central role in the induction and transmission of itch sensations. By targeting IL-31R, QX010N aims to alleviate severe and chronic pruritus, addressing a significant unmet medical need in dermatological diseases.

Targets

IL31RA (IL-31 receptor alpha)

Beyond the preview

Go deeper on QX010N.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QX010N.

Explore the full profile